Synthesis of novel thiazole and 1,3,4-thiadiazole derivatives incorporating phenylsulfonyl moiety

Article abstract of DOI:10.3987/COM-14-13020

Reaction of 1-(benzothiazol-2-yl)-2-phenylsulfonyl-1-ethanone (1) and 1-(1-methyl-1H-benzimidazol-2-yl)-2-(phenylsulfonyl)-1-ethanone (2) with phenyl isothiocyanate afforded the corresponding potassium salts 3 and 4, respectively. The potassium salts 3 an

Full text of DOI:10.3987/COM-14-13020

HETEROCYCLES, Vol. 89, No. 8, 2014
1827
HETEROCYCLES, Vol. 89, No. 8, 2014, pp.1827 - 1843. © 2014 The Japan Institute of Heterocyclic Chemistry
Received, 2nd May, 2014, Accepted, 24th June, 2014, Published online, 3rd July, 2014
DOI: 10.3987/COM-14-13020
SYNTHESIS OF NOVEL THIAZOLE AND 1,3,4-THIADIAZOLE
DERIVATIVES INCORPORATING PHENYLSULFONYL MOIETY
Ahmed E. M. Mekky,a,b Ahmed F. Darweesh,a Amani A. Salman,a and Ahmad
M. Faraga,*
aDepartment of Chemistry, Faculty of Science, Cairo University, Giza 12613,
b
Egypt; Current address: Chemistry Department, Faculty of Science, King
Abdulaziz University, North Jeddah, P.O. Box 80203, Jeddah 21589, Saudi
Arabia
*Corresponding author: E-mail: afarag49@yahoo.com
Abstract – Reaction of 1-(benzothiazol-2-yl)-2-phenylsulfonyl-1-ethanone (1)
and 1-(1-methyl-1H-benzimidazol-2-yl)-2-(phenylsulfonyl)-1-ethanone (2) with
phenyl isothiocyanate afforded the corresponding potassium salts 3 and 4,
respectively. The potassium salts 3 and 4 were converted into the corresponding
(Z)-1-(benzothiazol-2-yl)-3-mercapto-3-(phenylamino)-2-(phenylsulfonyl)
propenone
(5)
and
(Z)-1-(1-methylbenzimidazole-2-yl)-3-mercapto-3-
(phenylamino)-2-(phenylsulfonyl)propenone (6), respectively upon acidification
with HCl. The latter products were used as versatile building blocks for novel
1,3,4-thiadiazole derivatives via their reactions with the appropriate hydrazonyl
halides. They have been also utilized for the synthesis of thiazole ring systems
incorporating phenylsulfonyl moiety.
INTRODUCTION
Benzothiazole and benzimidazole derivatives are recognized as important heterocycles due to their
diverse pharmacological properties.1 Their derivatives have attracted continuing interest because of their
varied biological activities such as antiviral,2-5 antibacterial,6,7 antifungal,8-11 antitumour,12-15
anticancer,16,17 antitubercular,18,19 antimalarial,20 anticonvulsant,21 antihelminthic agentsin veterinary
medicine,22-24 analgesic,25,26 anti-inflammtory,27,28 antidiabetic agents,29 anti-HIV,30,31 anticoagulative
agents,32,33 antihypertensive,34,35 antineoplastic,36,37 anxiolytic agents.38,39 Many of their derivatives are
now included in many of commercialized drugs.40-42 On the other hand, β-ketosulfone moiety displays a

1828
HETEROCYCLES, Vol. 89, No. 8, 2014
broad range of synthetic potentiality.43,44 In continuation of our research work aiming at the synthesis of a
variety of heterocycles for biological screening,45-60 we report here on the utility of (Z)-1-(benzothiazol-2-
yl)-3-mercapto-3-(phenylamino)-2-(phenylsulfonyl)propenone (5) and (Z)-1-(1-methylbenzimidazole-2-
yl)-3-mercapto-3-(phenylamino)-2-(phenylsulfonyl)propenone (6) as reactive intermediates, for the
synthesis of the 1,3,4-thiadiazole and 1,3-thiazole heterocycles incorporating phenylsulfonyl moiety of
potential biological activity.
RESULTS AND DISCUSSION
Treatment of 1-(benzothiazol-2-yl)-2-(phenylsulfonyl)ethanone (1)46 and 1-(1-methyl-1H-benzimidazol-
2-yl)-2-(phenylsulfonyl)ethanone (2)46 with phenyl isothiocyanate, in DMF in the presence of potassium
hydroxide, at rt afforded the corresponding potassium salts 3 and 4, respectively. Treatment of these
intermediate salts with HCl afforded, in each case, a single product (as examined by TLC). The reaction
products
were
identified
as
(5)
(Z)-1-(benzothiazol-2-yl)-3-mercapto-3-(phenylamino)-2-
and (Z)-1-(1-methylbenzimidazole-2-yl)-3-mercapto-3-
(phenylsulfonyl)prop-2-en-1-one
(phenylamino)-2-(phenylsulfonyl)prop-2-en-1-one (6), respectively (Scheme 1). The IR spectra of
compounds 5 and 6 showed, in each case, a band near 3345 cm-1 due to NH group and strong absorption
bands at 1685 and 1680 cm-1 due to carbonyl functions.
O
O
O
O
Ph
O H
Ph
N
X
S
S
N
N Ph
SH
N
O
O
HCl
DMF/ KOH
rt, 6 h
+ PhNCS
X
X
SK
HN
Ph S
54-60%
O
Ph
3; X = S
4; X = NMe
O
5; X = S
1; X = S
2; X = NMe
6; X = NMe
(Z)-Configuration
O
N
SH
X
Ph S
NH
O
Ph
O
(E)-Configuration
Scheme 1
Compounds 5 and 6 were assigned the (Z) configuration which is stabilized by hydrogen bonding rather
than the (E) configuration which could suffer from steric hindrance. Compounds 5 and 6 react with 2-
bromoacetophenone (7a) and 2-bromo-4′-chloroacetophenone (7b), in EtOH under conventional heating
and under microwave conditions in the presence of an equivalent amount of triethylamine, to afford the
corresponding polysubstituted thiazole derivatives 8a,b and 9a,b, respectively (Scheme 2). The IR spectra
of the isolated products 8a and 9a showed strong absorption bands at 1685 and 1678 cm-1, respectively

HETEROCYCLES, Vol. 89, No. 8, 2014
1829
due to carbonyl functions. The 1H NMR spectra of 8a and 9a revealed in each case a characteristic singlet
signal near δ 6.65 due to thiazole proton. Their mass spectra showed, in each case, a peak corresponding
to the molecular ion (see Experimental Section).
Similarly, compounds 5 and 6 reacted with ethyl chloroacetate to afford, in each case, a single product
identified as (Z)-2-(2-(benzothiazol-2-yl)-2-oxo-1-(phenylsulphonyl)ethylidene)-3-phenylthiazolidin-4-
one (11) and
(Z)-2-(2-(1-methylbenzimiazol-2-yl)-2-oxo-1-(phenylsulphonyl)ethylidene)-3-phenyl-
1
thiazolidin-4-one (12), respectively (Scheme 2). The H NMR spectra of isolated products revealed
multiplet signals in the range δ 7.21-8.14 and 7.20-7.94, respectively characteristic for aromatic protons.
Their IR spectra showed bands at 1695, 1655 cm-1 for compound 11 and at 1678, and 1635 cm-1 for
compound 12, due to two carbonyl functions. The mass spectra of the reaction products revealed, in each
case, a peak corresponding to the molecular ion.
X
O
O
N
S
Ph
S
O
N
Ph
O
11; X = S
12; X = NMe
O
EtOH/Et3N
reflux, 6 h, 64-76%
Cl
OEt
micowave, 150 oC,
30 min, 83-93%
10
O
X
O
Cl
CN
X
Br
O
O
N
Ar
O
N
S
S
7a,b
13
Ph
5 6
;
Ph
O
EtOH/Et3N
EtOH/Et3N
reflux, 6 h, 85-86%
O
S
S
reflux, 6 h, 73-84%
microwave, 150 oC,
30 min, 88-90%
N
Ph
N
Ph
Ar
8a,b; X = S
H2N
14; X = S
O
9a,b
; X = NMe
15
; X = NMe
Cl EtOH/Et3N
reflux, 6 h, 80-83%
Me
16
7, 8, 9
Ar
O
S
a
b
C6H5
4-ClC6H4
X
O
O
Ph
N
S
N
Ph
Me
17
18
; X = S
; X = NMe
Scheme 2

1830
HETEROCYCLES, Vol. 89, No. 8, 2014
In a similar manner, compounds 5 and 6 reacted with chloroacetonitrile and with chloroacetone to afford
the products identified as (Z)-2-(4-amino-3-phenylthiazol2-(3H)-ylidene-1-(benzothiazol-2-yl)-2-
(phenylsulfonyl)ethanone (14), (Z)-2-(4-amino-3-phenylthiazol-2-(3H)-ylidene-1-(1-methylbenzimidazol-
2-yl)-2-(phenylsulfonyl)ethanone (15), (Z)-1-(benzothiazol-2-yl)-2-(4-methyl-3-phenylthiazol-2-(3H)-
ylidene)-2-phenylsulphonyl)ethanone (17) and (Z)-1-(benzimidazol-2-yl)-2-(4-methyl-3-phenylthiazol-2-
(3H)ylidene)-2-(phenylsulphonyl)ethanone (18), respectively (Scheme 2). The IR spectra of the isolated
1
products 14 and 15, revealed, in each case, bands near 3331 and 3325 cm-1 due to NH2 group. The H
NMR spectrum of compound 17, taken as an example, revealed singlet signals at δ 1.73 and 5.79 due to
CH3 and CH-thiazole ring protons, respectively and a multiplet signal in region δ 6.91-8.14 due to
aromatic protons.
A plausible mechanism illustrating the formation of compounds 8, 9, 11, 12, 14, 15, 17 and 18 is depicted
in Scheme 3.
-HCl
X
O
5; 6
Cl
CN
X
O
+
O
O
N
S
N
S
Ph
Ph
O
13
Et3N
O
S
Z
O
S
- HZ
R
Ph NH
N
Ph
7; 10; 16
Z = Cl, Br
N
H2N
14; 15
X
O
X
N
O
O
O
N
S
-H2O or -EtOH
S
Ph
Ph
S
O
S
O
N
Ph
Ph NH
O
X = S, NMe
R=Me; R'=Me
R=Ar; R'= Ar
R= OEt; R'= OH
R
R
8; 9; 11; 12; 17; 18
Scheme 3
Treatment of compounds 5 and 6 with 2-oxo-N-arylpropanehydrazonyl chlorides 19a-d, afforded in each
case, only one isolable product (as examined by TLC) (Scheme 4). The elemental analyses and spectral
data of the reaction products were in complete agreement with the 1,3,4-thiadiazole structures 20a-d and
21a-d. For example, the IR spectra of the isolated products revealed, in each case, the appearance of the
carbonyl absorption bands near 1675, 1645 cm-1 for compounds 20a-d and 1665, 1625 cm-1 in case of
compounds 21a-d. Their mass spectra revealed, in each case, a peak corresponding to the molecular ion.

HETEROCYCLES, Vol. 89, No. 8, 2014
1831
O
S
O
X
Ph
O
N
EtOH/ Et3N
Ar
N
S
Me
5 6
;
+
Me
N
H
O
rt, 12 h, 75-81%
N
Cl
19a-d
N
Ar
O
20a-d; X = S
21a-d; X = NMe
19, 20, 21 Ar
a
b
c
d
C6H5
4-MeC6H4
4-ClC6H4
4-OMeC6H4
Scheme 4
When compounds 5 and 6 were treated with N-phenylbenzohydrazonyl chloride (22) they afforded the
corresponding (Z)-1-(benzothiazol-2-yl)-2-(3,5-diphenyl-1,3,4-thiadiazole-2-(3H)ylidene)-2-(phenyl-
sulfonyl)ethanone (23) and (Z)-2-(3,5-diphenyl-1,3,4-thiadiazole-2-(3H)-ylidene)-1-(1-methyl-1H-
benzimidazol-2-yl)-2-(phenylsulfonyl)ethanone (24), respectively (Scheme 5).
X
Cl
O
O
N
H
N
EtOH/ Et3N
S
N
N
5 6
;
+
Ph
N
Ph
Ph
rt, 12 h, 72-78%;
microwave, 150 oC,
20 min, 89-92%
O
S
22
Ph
Ph
23; X = S
24; X = NMe
Scheme 5
In a similar manner, compounds 5 and 6 react with the hydrazonyl halides 25a-c, under the same reaction
conditions, to afford, in each case, a single product. The isolated products were identified as (Z)-ethyl 4-
aryl-5-(2-(benzothiazol-2-yl)-2-oxo-1-((phenylsulfonyl)ethylidene)-4,5-dihyro-1,3,4-thiadiazole-2-
carboxylate derivatives 26a-c, and (Z)-ethyl 4-aryl-5-(2-(1-methylbenzimidazol-2-yl)-2-oxo-1-
((phenylsulfonyl)ethylidene)-4,5-dihyro-1,3,4-thiadiazole-2-carboxylate derivatives 27a-c, respectively
(Scheme 6). The structures of the reaction products were confirmed on the basis of their elemental
analyses and spectral data. For example, the IR spectra of the isolated products revealed, in each case, the
appearance of two strong carbonyl absorption bands near 1680 and 1654 cm-1. Their mass spectra
revealed, in each case, a peak corresponding to the molecular ion (see Experimental Section).
Compounds 5 and 6 reacted also with the hydrazonyl halides 28 and 31 and afforded the corresponding
(Z)-1-(benzothiazol-2-yl)-2-(5-benzoyl-3-phenyl-1,3,4-thiadiazole-2-(3H)-ylidene)-2-(phenylsulfonyl)-

1832
HETEROCYCLES, Vol. 89, No. 8, 2014
ethanone (29), (Z)-1-(1-methyl-1H-benzimidazol-2-yl)-2-(5-benzoyl-3-phenyl-1,3,4-thiadiazole-2-(3H)-
ylidene)-2-(phenylsulfonyl)ethanone (30), (Z)-5-(2-(benzothiazol-2-yl)-2-oxo-1-(phenylsulfonyl)ethy-
lidene)-N-4-diphenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxamide (32) and (Z)-5-(2-(1-methyl-1H-
benzimidazol-2-yl)-2-oxo-1-(phenylsulfonyl)ethylidene)-N-4-diphenyl-4,5-dihydro-1,3,4-thiadiazole-2-
carboxamide (33), respectively (Scheme 6). The IR spectra of the isolated products 32 and 33 revealed, in
1
each case, an absorption band near 3395 cm-1 due to NH function. The H NMR spectrum of compound
32 showed, in addition to aromatic proton multiplet in the region 6.80-8.15 ppm, a D2O- exchangeable
signal at 10.60 ppm due to NH proton
Cl
Cl
H
H
EtO
N
PhHN
N
N
Ar
N
Ph
O
O
31
25a-c
5 6
;
EtOH/Et3N
rt, 12 h, 71-81%
microwave, 150 °C,
20 min, 92-94%
EtOH/Et3N
rt, 12 h, 78-80%
Br
H
EtOH/Et3N
Ph
rt,12 h, 80-82%
Ph
N
N
O
28
X
X
X
O
O
O
O
O
O
N
N
N
N
S
N
S
R
S
Ph
Ph
O
O
O
S
S
N
N
S
Ph
N
Ar
Ph
NHPh
OEt
Ph
N
O
O
O
29; X = S
26a-c; X = S
27a-c; X = NMe
32
; X = S
33
; X = NMe
30; X = NMe
Ar
25, 26, 27
a
b
c
C6H5
4-MeC6H4
4-ClC6H4
Scheme 6
A general reasonable mechanism for the reaction of compounds 5 and 6 with the hydrazonyl halides
19a-d, 22, 25a-c, 28 and 31 leading to the formation of the products 20, 21, 23, 24, 26, 27, 29, 30, 32 and
33 is shown in Scheme 7.

HETEROCYCLES, Vol. 89, No. 8, 2014
1833
Z
H
X
Et3N
O
N
O
5; 6
+
N
R
N
Ar
S
-
HZ
Ph
O
S
19; 22; 25; 28; 31
PhHN
HN
R
N
Ar
X
O
O
N
X
N
S
O-
O
-PhNH2
R
S
Ph
S
O
Ar
S
O
PhHN
N
R
N
N
R
N
Ar
20; 21; 23; 24; 26; 27; 29; 30; 32; 33
X = S, NMe R= CONHPh, COMe, CO2Et, Ph, COPh
Ar = C6H5, 4-MeC6H4, 4-ClC6H4, 4-OMeC6H4
Z = Cl, Br
Scheme 7
EXPERIMENTAL
Melting points were determined in open glass capillaries with a Gallenkamp apparatus. The IR spectra
were recorded using KBr disks on a Pye Unicam SP 3-300 or a Shimadzu FTIR 8101 PC IR
spectrophotometer. The NMR spectra were recorded with a Varian Mercury VXR-300 NMR
spectrometer at 300 and 75 MHz for 1H and 13C NMR spectra, respectively, using CDCl3 and DMSO-d6
as solvents. Chemical shifts were related to that of the solvent. Mass spectra (EI) were obtained at 70 eV
with a Shimadzu GCMQP 1000 EX spectrometer. TLC analyses were performed using pre-coated silica
gel 60778 plates (Fluka), and the spots were visualized with UV light at 254 nm. Fluka silica gel 60741
(70–230 mesh) was used for flash column chromatography. Microwave experiments were carried out
using a CEM Discover LabMate microwave apparatus (300 W with ChemDriver Software).
1-(Benzothiazol-2-yl)-2-(phenylsulfonyl)ethanone (1) and 1-(1-methyl-1H-benzimidazol-2-yl)-2-
(phenylsulfonyl)ethanone (2) were prepared according to our reported procedure.46
Reaction of 1-(benzothiazol-2-yl)-2-(phenylsulfonyl)ethanone (1) and 1-(1-methyl-1H-benzimidazol-
2-yl)-2-(phenylsulfonyl)ethanone (2) with phenyl isothiocyanate.
General procedure:
To a stirred solution of KOH (0.56 g, 10 mmol) in DMF (20 mL), the appropriate ketosulfone 1 or 2 (l0

1834
HETEROCYCLES, Vol. 89, No. 8, 2014
mmol) was added. After stirring for 30 min, phenyl isothiocyanate (1.35 g, 10 mmol) was added to the
resulting mixture. Stirring was continued for 6 h, then poured over crushed ice containing HCl. The
formed solid product was filtered off, washed with water, dried and finally recrystallized from
EtOH/DMF to afford 1-(benzothiazol-2-yl)-3-mercapto-3-phenylamino-3-phenylsulphonylprop-2-en-1-
one (5) and 1-(1-methylbenzimidazol-2-yl)-3-mercapto-3-phenylamino-3-phenylsulphonylprop-2-en-1-
one (6), respectively.
(Z)-1-(Benzothiazol-2-yl)-3-mercapto-3-phenylamino-3-phenylsulfonylprop-2-en-1-one (5): Yield
1
(60%), mp 113-115 °C; IR (KBr) vmax/cm–1: 3345 (NH), 2580 (SH), 1685 (CO); H NMR (DMSO-d6) δ
4.21 (s, 1H, D2O-exchangable, NH), 6.57-8.14 (m, 14H, ArH), 11.3 (s, 1H, D2O-exchangable, SH); MS
(m/z, %): 452 (M+, 100%); Anal. Calcd for C22H16N2O3S3 (452.57): C, 58.39; H, 3.56; N, 6.19; S, 21.26%.
Found: C, 58.43; H, 3.49; N, 6.12; S, 21.19%.
(Z)-1-(1-Methylbenzimidazol-2-yl)-3-mercapto-3-phenylamino-3-phenylsulphonylprop-2-en-1-one
1
(6): Yield (54%), mp 117-119 °C; IR (KBr) vmax/cm–1: 3346 (NH), 2570 (SH), 1680 (CO); H NMR
(DMSO-d6) δ 4.02 (s, 3H, NCH3), 4.21 (s, 1H, D2O-exchangable, NH), 6.39-7.93 (m, 14H, ArH), 11.3 (s,
1H, D2O-exchangable, SH); MS (m/z, %): 449 (M+, 100%); Anal. Calcd for C23H19N3O3S2 (449.55): C,
61.45; H, 4.26; N, 9.35; S, 14.27%. Found: C, 61.43; H, 4.29; N, 9.31; S, 14.30%.
Reaction of compounds 5 and 6 with α-haloketones 7a,b, ethyl bromoacetate, chloroacetonitrile
and chloroacetone.
(A) Thermal method
General procedure:
To a solution of compounds 5 and 6 (1 mmol) and the appropriate α-haloketones 7, ethyl chloroacetate,
chloroacetonitrile or chloroacetone (1 mmol), in EtOH (20 mL), was added triethylamine (0.5 mL). The
reaction mixture was refluxed for 6 h, and then allowed to cool. The formed solid product was filtered off,
washed with EtOH, dried and finally recrystallized from DMF/H2O to afford the corresponding thiazole
derivatives 8a,b, 9a,b, 11, 12, 14, 15, 17 and 18, respectively.
(B) Microwave method (MW)
General procedure:
An ethanolic mixture of compounds 5 or 6 (1 mmol) and the appropriate α-haloketones 7, ethyl
chloroacetate, chloroacetonitrile or chloroacetone (1 mmol) and few drops of triethylamine were added in
a process vial. The vial was capped properly and irradiated with microwave under pressurized conditions
(17.2 bars, 150 °C) for 30 min. The reaction mixture was evaporated under reduced pressure and residual
solid was taken in ethanol then collected by filtration, washed with ethanol, dried and finally
recrystallized from the proper solvent to afford the products 8a, 9a, 11 and 12, respectively.
(Z)-1-(Benzothiazol-2-yl)-2-(3,4-diphenylthiazol-2-(3H)-ylidene)-2(phenylsulfonyl)ethanone
(8a):

HETEROCYCLES, Vol. 89, No. 8, 2014
1835
1
Yield: 88% (microwave); 73% (thermal), mp 170-172 °C; IR (KBr) vmax/cm–1: 1685 (CO); H NMR
13
(DMSO-d6) δ 6.65 (s, 1H, thiazol-5-CH), 6.86-8.14 (m, 19H, ArH); C NMR (DMSO-d6) δ 107.11,
118.80, 120.95, 121.60, 124.15, 124.28, 125.27, 128.09, 128.45, 128.51, 128.76, 129.33, 129.80, 129.84,
131.16, 133.43, 137.23, 137.49, 142.19, 144.20, 155.10, 156.54, 162.69, 182.37; MS (m/z, %): 552 (M+,
100%); Anal. Calcd for C30H20N2O3S3 (552.69): C, 65.19; H, 3.65; N, 5.07; S, 17.40%. Found: C, 65.23;
H, 3.59; N, 5.01; S, 17.31%.
(Z)-1-(Benzothiazol-2-yl)-2-(4-(4-chlorophenyl)(3-phenyl)thiazol-2-(3H)-ylidene)-2-(phenylsulfonyl)-
1
ethanone (8b): Yield (84%), mp 179-181 °C; IR (KBr) vmax/cm–1: 1695 (CO); H NMR (DMSO-d6) δ
6.65 (s, 1H, thiazole - 5- H), 6.83-8.14 (m, 18H, ArH); MS (m/z, %): 586 (M+); Anal. Calcd for
C30H19ClN2O3S3 (587.13): C, 61.37; H, 3.26; N, 4.77; S, 16.38%. Found: C, 61.33; H, 3.23; N, 4.69; S,
16.34%.
(Z)-1-(1-Methylbenzimidazol-2-yl)-2-(3,4-diphenylthiazol-2-(3H)-ylidene)-2-(phenylsulfonyl)-
ethanone (9a): Yield: 90% (microwave); 75% (thermal), mp 190-192 °C; IR (KBr) vmax/cm–1: 1678 (CO);
13
1H NMR (DMSO-d6) δ 4.02 (s, 3H, NCH ), 6.65 (s, 1H, thiazole-5- CH), 7.20-7.97 (m, 19H, ArH); C
3
NMR (DMSO-d6) δ 32.11, 107.16, 113.29, 114.87, 118.80, 120.95, 121.60, 122.71, 124.15, 124.28,
125.27, 128.09, 128.45, 128.51, 128.76, 129.33, 129.80,129.84, 131.16, 133.43, 134.53, 137.49, 139.11,
142.19, 144.20, 156.57, 182.30; MS (m/z, %): 549 (M+, 100%); Anal. Calcd for C31H23N3O3S2 (549.66):
C, 67.74; H, 4.22; N, 7.64; S, 11.67%. Found: C, 67.71; H, 4.19; N, 7.69; S, 11.73%.
(Z)-2-(4-(4-Chlorophenyl)-3-phenylthiazol-2-(3H)-ylidene)-1-(1-methylbenzimidazol-2-yl)-
1
2-(phenylsulfonyl)ethanone (9b): Yield (84%), mp 188-190 °C; IR (KBr) vmax/cm–1: 1681 (CO); H
NMR (DMSO-d6) δ 4.02 (s, 3H, NCH3), 6.65 (s, 1H, thiazole-5-H), 6.93-7.94 (m, 18H, ArH); MS
(m/z, %): 584 (M+, 100%); Anal. Calcd for C31H22ClN3O3S2 (584.11): C, 63.74; H, 3.80; N, 7.19; S,
10.98%. Found: C, 63.69; H, 3.76; N, 7.13; S, 10.91%.
(Z)-2-(2-(Benzothiazol-2-yl)-2-oxo-1-(phenylsulphonyl)ethylidene)-3-phenylthiazolidin-4-one (11):
1
Yield: 93% (microwave); 76% (thermal), mp 236-238 °C; IR (KBr) vmax/cm–1: 1695 and 1655 (CO); H
NMR (DMSO-d6) δ 4.11 (s, 2H, thiazole - 5-H), 7.21-8.14 (m, 14H, ArH); MS (m/z, %): 492 (M+,
100%); Anal. Calcd for C24H16N2O4S3 (492.59): C, 58.52; H, 3.27; N, 5.69; S, 19.53%. Found: C, 58.50;
H, 3.23; N, 5.75; S, 19.54%.
(Z)-2-(2-(1-Methylbenzimiazol-2-yl)-2-oxo-1-(phenylsulphonyl)ethylidene)-3-phenylthiazolidin-4-one
(12): Yield: 83% (microwave); 64% (thermal), mp 200-202 °C; IR (KBr) vmax/cm–1: 1678 and 1635 (CO);
1H NMR (DMSO-d6) δ 4.02 (s, 3H, NCH3) 4.11 (s, 2H, thiazole-5-CH), 7.20-7.94 (m, 14H, ArH); MS
(m/z, %): 489 (M+, 100%); Anal. Calcd for C25H19N3O4S2 (489.57): C, 61.33; H, 3.91; N, 8.58; S, 13.10%.
Found: C, 61.24; H, 3.95; N, 8.60; S, 13.11%.

1836
HETEROCYCLES, Vol. 89, No. 8, 2014
(Z)-2-(4-Amino-3-phenylthiazol-2-(3H)-ylidene-1-(benzothiazo-2-yl)-2-(phenylsulfonyl)ethanone
(14): Yield (85%), mp 282-284 °C; IR (KBr) vmax/cm–1: 3331 (NH2), 1640 (CO); 1H NMR (DMSO-d6) δ
5.20 (s, 2H, NH2), 5.76 (s, 1H, thiazole-5-CH), 6.91-8.14 (m, 14H, ArH); MS (m/z, %): 491 (M+, 100%);
Anal. Calcd for C24H17N3O3S3 (491.61): C, 58.64; H, 3.49; N, 8.55; S, 19.57%. Found: C, 58.68; H, 3.45;
N, 8.48; S, 19.50%.
(Z)-2-(4-Amino-3-phenylthiazol-2-(3H)-ylidene-1-(1-methylbenzimidazo-2-yl)-2-(phenylsulfonyl)-
1
ethanone (15): Yield (85%), mp 246-248 °C; IR (KBr) vmax/cm–1: 3325 (NH2), 1635 (CO); H NMR
(DMSO-d6) δ 4.02 (s, 3H, NCH3), 5.20 (s, 2H, D2O-exchange, NH2), 5.76 (s, 1H, thiazole-5-CH), 6.91-
7.83 (m, 14H, ArH); MS (m/z, %): 488 (M+, 100%); Anal. Calcd for C25H20N4O3S2 (488.58): C, 61.46; H,
4.13; N, 11.47; S, 13.13%. Found: C, 61.43; H, 4.16; N, 11.49; S, 13.11%.
(Z)-1-(Benzothiazol-2-yl)-2-(4-methyl-3-phenylthiazol-2-(3H)ylidene-2-(phenylsulphonyl)ethanone
(17): Yield (80%), mp 181-183 °C; IR (KBr) vmax/cm–1: 1638 (CO); 1H NMR (DMSO-d6) δ 1.73 (s, 3H,
13
CH3), 5.79 (s, 1H, thiazole-5-CH), 6.91-8.14 (m, 14H, ArH); C NMR (DMSO-d6) δ 20.05, 107.15,
118.76, 121.00, 121.64, 124.23, 124.32, 125.28, 128.81, 129.27, 129.83, 131.11, 133.54, 137.26, 139.03,
142.30, 144.65, 155.29, 156.55, 162.71, 182.28; MS (m/z, %): 490 (M+, 100%); Anal. Calcd for
C25H18N2O3S3 (490.62): C, 61.20; H, 3.70; N, 5.71; S, 19.61%. Found: C, 61.13; H, 3.64; N, 5.65; S,
19.55%.
(Z)-1-Methyl-(benzimidazol-2-yl)-2-(4-methyl-3-phenylthiazol-2-(3H)-ylidene)-2-(phenylsulphonyl)-
1
ethanone (18): Yield (83%), mp 170-172 °C; IR (KBr) vmax/cm–1: 1636 (CO); H NMR (DMSO-d6) δ
1.71 (s, 3H, CH3), 4.02 (s, 3H, NCH3), 5.79 (s, 1H, thiazole-5-CH), 6.35-7.83 (m, 14H, ArH); 13C NMR
(DMSO-d6) δ 19.87, 32.12, 107.16, 113.29, 114.87, 118.80, 121.60, 124.15, 124.28, 125.27, 128.51,
129.33, 129.80, 131.16, 133.40, 134.42, 137.53, 139.15, 142.11, 144.20, 156.55, 182.30; MS (m/z, %):
487 (M+, 100%); Anal. Calcd for C26H21N3O3S2 (487.59): C, 64.04; H, 4.34; N, 8.62; S, 13.15%. Found:
C, 64.09; H, 4.28; N, 8.59; S, 13.09%.
Reaction of compounds 5 and 6 with hydrazonyl halides 19a-d, 22, 25a-c, 28 and 31.
(A) Thermal method
General procedure:
To a mixture of compounds 5 or 6 (1 mmol) in EtOH (20 mL), triethylamine (0.5 mL), the appropriate
hydrazonyl halide 19a-d, 22, 25a-c, 28 or 31 (1 mmol) was added portion wise over a period of 30 min.
The reaction mixture was stirred at room temperature for 12 h, during which hydrazonyl halide went into
solution and a yellowish-red colored product precipitated. The solid product was filtered off, washed with
water, dried and finally recrystallized from EtOH/DMF to afford the corresponding 1,3,4-thiadiazole

HETEROCYCLES, Vol. 89, No. 8, 2014
1837
derivatives 20a-d, 21a-d, 23, 24, 26a-c, 27a-c, 29, 30, 32 and 33, respectively.
(B) Microwave method
General procedure:
To a mixture of compounds 5 or 6 (1 mmol) and the appropriate hydrazonyl halide 22 or 25a (1 mmol)
few drops of triethylamine were added in a process vial. The vial was capped properly and irradiated by
microwave under pressurized conditions (17.2 bars, 150 oC) for 20 min. A yellowish-red colored product
was formed. The solid product was filtered off, washed with water, dried and recrystallized from
EtOH/DMF to afford the corresponding 1,3,4-thiadiazole derivatives 23, 24, 26a and 27a, respectively.
(Z)-2-(5-Acetyl-3-phenyl-1,3,4-thiadiazol-2-(3H)-ylidene)-1-(benzothiazol-2-yl)-2-(phenylsulphonyl)-
1
ethanone (20a): Yield (81%), mp 210-212 °C; IR (KBr) vmax/cm–1: 1675, 1645 (CO), 1598 (C=N); H
NMR (DMSO-d6) δ 2.22 (s, 3H, CH3), 7.23-8.14 (m, 14H, ArH); 13C NMR (DMSO-d6) δ 24.7, 102.35,
114.33, 118.71, 119.79, 122.53, 123.43, 124.18, 126.93, 127.23, 128.63, 129.52, 132.98, 136.55, 142.54,
143.74, 152.02, 151.32, 155.50, 182.34, 192.87; MS (m/z, %): 519 (M+, 100%); Anal. Calcd for
C25H17N3O4S3 (519.62): C, 57.79; H, 3.30; N, 8.09; S, 18.51%. Found: C, 57.71; H, 3.23; N, 8.00; S,
18.44%.
(Z)-2-(5-Acetyl-3-p-tolyl-1,3,4-thiadiazol-2(3H)-ylidene)-1(benzothiazol-2-yl)-2-(phenylsulfonyl)-
1
ethanone (20b): Yield (76%), mp 258-260 °C; IR (KBr) vmax/cm–1:
, 1637 (CO),
(C=N); H
1675
1606
NMR (DMSO-d6) δ 2.22 (s, 3H, CH3), 2.42 (s, 3H, CH3) 7.23-8.14 (m, 13H, ArH); MS (m/z, %): 533
(M+, 100%); Anal. Calcd for C26H19N3O4S3 (533.64): C, 58.52; H, 3.59; N, 7.87; S, 18.03%. Found: C,
58.47; H, 3.51; N, 7.80; S, 17.98%.
(Z)-2-(5-Acetyl-3-(4-chlorophenyl-1,3,4-thiadiazol-2(3H)-ylidene)-1-(benzothiazol-2-yl)-2-(phenyl-
sulfonyl)ethanone (20c): Yield (78%), mp 228-230 °C; IR (KBr) vmax/cm–1: 1673, 1642 (CO), 1603
1
(C=N); H NMR (DMSO-d6) δ 2.22 (s, 3H, CH3), 7.34-8.14 (m, 13H, ArH); MS (m/z, %): 553 (M+,
100%); Anal. Calcd for C25H16ClN3O4S3 (554.06): C, 54.19; H, 2.91; N, 7.58; S, 17.36%. Found: C,
54.11; H, 2.87; N, 7.53; S, 17.29%.
(Z)-2-(5-Acetyl-3-(4-methoxyphenyl-1,3,4-thiadiazol-2(3H)-ylidene)-1-(benzothiazol-2-yl)-2-
(phenylsulfonyl)ethanone (20d): Yield (73%), mp 186-188 °C; IR (KBr) vmax/cm–1: 1671, 1645 (CO),
1
1596 (C=N); H NMR (DMSO-d6) δ 2.22 (s, 3H, CH3), 3.84 (s, 3H, OCH3), 7.14-8.13 (m, 13H, ArH);
MS (m/z, %): 549 (M+, 100%); Anal. Calcd for C26H19N3O5S3 (549.64): C, 56.81; H, 3.48; N, 7.65; S,
17.50%. Found: C, 56.78; H, 3.41; N, 7.57; S, 17.48%.
(Z)-2-(5-Acetyl-3-phenyl-1,3,4-thiadiazol-2-(3H)-ylidene)1-(1-methylbenzimidazol-2-yl-)-2-
(phenylsulphonyl)ethanone (21a): Yield (79%), mp 202-204 °C; IR (KBr) vmax/cm–1: 1665, 1625 (CO),
1
1588 (C=N); H NMR (DMSO-d6) δ 2.21 (s, 3H, CH3), 4.02 (s, 3H, NCH3), 6.67-7.79 (m, 14H, ArH);

1838
HETEROCYCLES, Vol. 89, No. 8, 2014
MS (m/z, %): 516 (M+, 100%); Anal. Calcd for C26H20N4O4S2 (516.59): C, 60.45; H, 3.90; N, 10.85; S,
12.41%. Found: C, 60.36; H, 3.86; N, 10.78; S, 12.37%.
(Z)-2-(5-Acetyl-3-p-tolyl-1,3,4-thiadiazol2(3H)-ylidene)-1-(1-methylbenzimidazol-2-yl)-2-
(phenylsulfonyl)ethanone (21b): Yield (75%), mp 210-212 °C; IR (KBr) vmax/cm–1: 1667, 1623 (CO),
1597 (C=N); 1H NMR (DMSO-d6) δ 2.21 (s, 3H, CH3), 2.32 (s, 3H, CH3), 4.02 (s, 3H, NCH3), 6.98-
7.89 (m, 13H, ArH); MS (m/z, %): 530 (M+, 100%); Anal. Calcd for C27H22N4O4S2 (530.62): C, 61.12; H,
4.18; N, 10.56; S, 12.09%. Found: C, 61.06; H, 4.08; N, 10.49; S, 12.02%.
(Z)-2-(5-Acetyl-3-(4-chlorophenyl)1,3,4thiadiazol-2(3H)-ylidene)-1-(1-methylbenzimidazol-2-yl)-2-
(phenylsulfonyl)ethanone (21c): Yield (80%), mp 296-298 °C; IR (KBr) vmax/cm–1: 1666, 1630 (CO),
1605 (C=N); 1H NMR (DMSO-d6) δ 2.21 (s, 3H, CH3), 4.02 (s, 3H, NCH3), 7.11-7.99 (m, 13H, ArH);
13C NMR (DMSO-d6): δ 24.74, 32.07, 106.62, 111.73, 114.32, 121.43, 123.95, 126.45, 127.94, 129.23,
129.43, 134.02, 137.06, 139.41, 140.82, 142.31, 145.22, 146.31, 153.37, 160.05, 182.34, 190.53; MS
(m/z, %): 550 (M+, 100%); Anal. Calcd for C26H19ClN4O4S2 (551.04): C, 56.67; H, 3.48; N, 10.17; S,
11.64%. Found: C, 56.70; H, 3.46; N, 10.13; S, 11.71%.
(Z)-2-(5-Acetyl-3-(4-methoxyphenyl)1,3,4-thiadiazol-2(3H)-ylidene)-1-(1-methylbenzimidazol-2-yl)-
2-(phenylsulfonyl)ethanone (21d): Yield (80%), mp 181-183 °C; IR (KBr) vmax/cm–1: 1664, 1627 (CO),
1593 (C=N); 1H NMR (DMSO-d6) δ 2.21 (s, 3H, CH3), 3.79 (s, 3H, OCH3), 4.02 (s, 3H, NCH3), 6.84-
7.99 (m, 13H, ArH); MS (m/z, %): 546 (M+, 100%); Anal. Calcd for C27H22N4O5S2 (546.62): C, 59.33; H,
4.06; N, 10.25; S, 11.73%. Found: C, 59.24; H, 4.00; N, 10.17; S, 11.67%.
(Z)-1-(Benzothiazol-2-yl)-2-(3,5-diphenyl-1,3,4-thiadiazole-2-(3H)ylidene)-2-(phenylsulfonyl)ethano
ne (23): Yield: 89% (microwave); 72% (thermal), mp 254-256 °C; IR (KBr) vmax/cm–1: 1665 (CO), 1630
(C=N); 1H NMR (DMSO-d6) δ 6.80-8.14 (m, 19H, ArH); MS (m/z, %): 553 (M+, 100%); Anal. Calcd for
C29H19N3O3S3 (553.67): C, 62.91; H, 3.46; N, 7.59; S, 17.37%. Found: C, 62.86; H, 3.39; N, 7.50; S,
17.28%.
(Z)-2-(3,5-Diphenyl-1,3,4-thiadiazole-2-(3H)-ylidene)-1-(1-methyl-1H-benzimidazol-2-yl)-2-
(phenylsulfonyl)ethanone (24): Yield: 92% (microwave); 78% (thermal), mp 188-190 °C; IR (KBr)
1
vmax/cm–1: 1661 (CO), 1595 (C=N); H NMR (DMSO-d6) δ 4.02 (s, 3H, NCH3), 6.80-7.92 (m, 19H,
ArH); MS (m/z, %): 550 (M+, 100%); Anal. Calcd for C30H22N4O3S2 (550.65): C, 65.44; H, 4.03; N,
10.17; S, 11.65%. Found: C, 65.45; H, 3.97; N, 10.11; S, 11.57 %.
(Z)-Ethyl 5-(2-(benzothiazol-2-yl)-2-oxo-1-(phenylsulfonyl)ethylidene)-4-phenyl-4,5,di-hydro-1,3,4-
thiadiazole-2-carboxylate (26a): Yield: 94% (microwave); 77% (thermal), mp 252-254 °C; IR (KBr)
1
vmax/cm–1: 1680, 1654 (CO), 1598 (C=N); H NMR (DMSO-d6) δ 1.25 (t, 3H, J = 7.2 Hz, CH3) 4.25 (q,
2H, J = 7.2 Hz, CH2), 6.80-8.14 (m, 14H, ArH); 13C NMR (DMSO-d6) δ 14.19, 61.30, 113.25, 118.60,

HETEROCYCLES, Vol. 89, No. 8, 2014
1839
118.98, 119.84, 121.91, 122.90, 124.15, 124.27, 125.32, 128.34, 129.24, 129.51, 133.40, 139.60,
143.03, 147.25, 155.11, 159.70, 162.73, 182.30; MS (m/z, %): 549 (M+, 100%); Anal. Calcd for
C26H19N3O5S3 (549.64): C, 56.81; H, 3.48; N, 7.65; S, 17.50%. Found: C, 56.76; H, 3.41; N, 7.59 S,
17.44%.
(Z)-Ethyl 5-(2-(benzothiazol-2-yl)-2-oxo-1-(phenylsulfonyl)ethylidene)-p-tolyl-4,5-di-hydro-
1,3,4-thiadiazole-2-carboxylate (26b): Yield (79%), mp 249-251 °C; IR (KBr) vmax/cm–1: 1680, 1653
1
(CO), 1605 (C=N); H NMR (DMSO-d6) δ 1.25 (t, 3H, J = 7.2 Hz, CH3), 2.32 (s, 3H, CH3), 4.25 (q,
2H, J = 7.2 Hz, CH2), 6.82-8.14 (m, 13H, ArH); MS (m/z, %): 563 (M+, 100%); Anal. Calcd for
C27H21N3O5S3 (563.67): C, 57.53; H, 3.76; N, 7.45; S, 17.07 %. Found: C, 57.45, H, 3.70; N, 7.38 S,
16.99%.
(Z)-Ethyl 5-(2-(benzothiazol-2-yl)-2-oxo-1-(phenylsulfonyl)ethylidene)-4-chlorophenyl-4,5-dihydro-
1,3,4-thiadiazole-2-carboxylate (26c): Yield (81%), mp 264-266 °C; IR (KBr) vmax/cm–1: 1680, 1654
(CO), 1604 (C=N); 1H NMR (DMSO-d6) δ 1.25 (t, 3H, J = 7.2 Hz, CH3), 4.25 (q, 2H, J = 7.2 Hz, CH2),
6.88-8.14 (m, 13H, ArH); MS (m/z, %): 583 (M+, 100%); Anal. Calcd for C26H18ClN3O5S3 (584.09): C,
53.46; H, 3.11; N, 7.19; S, 16.47%. Found: C, 53.37; H, 3.02; N, 7.11; S, 16.40%.
(Z)-Ethyl 5-(2-(1-methylbenzimidazol-2-yl)-2-oxo-1-(phenylsulfonyl)ethylidene)-p-phenyl-4,5,-
dihydro-1,3,4-thiadiazole-2-carboxylate (27a): Yield 92% (microwave); 71% (Thermal), mp
245-247 °C; IR (KBr) vmax/cm–1: 1678, 1652 (CO), 1601 (C=N); 1H NMR (DMSO-d6): δ 1.25 (t, 3H, J =
7.2 Hz, CH3), 4.02 (s, 3H, NCH3), 4.25 (q, 2H, J = 7.2 Hz, CH2), 6.80-7.83 (m, 14H, ArH); 13C NMR
(DMSO-d6): δ 14.16, 32.19, 61.31, 113.40, 118.66, 119.07, 122.75, 122.93, 124.11, 124.30, 128.44,
128.54, 129.11, 133.60, 134.19, 138.30, 141.23, 142.12, 147.01, 155.83, 159.75, 164.11, 182.32; MS
(m/z, %): 546 (M+, 100%); Anal. Calcd for C27H22N4O5S2 (546.62): C, 59.33; H, 4.06; N, 10.25; S,
11.73%. Found: C, 59.27; H, 4.01; N, 10.19 S, 11.68%.
(Z)-Ethyl 5-(2-(1-methylbenzimidazol-2-yl)-2-oxo-1-(phenylsulfonyl)ethylidene)-p-tolyl-4,5-dihyro-
1,3,4-thiadiazole-2-carboxylate (27b): Yield (77%), mp 235-237 °C; IR (KBr) vmax/cm–1: 1682, 1651
(CO), 1607 (C=N); 1H NMR (DMSO-d6) δ 1.29 (t, 3H, J = 7.2 Hz, CH3), 2.33 (s, 3H, CH3), 4.02 (s, 3H,
NCH3), 4.25 (q, 2H, J = 7.2 Hz, CH2), 6.72-8.14 (m, 13H, ArH); MS (m/z, %): 560 (M+, 100%); Anal.
Calcd for C28H24N4O5S2 (560.64): C, 59.98; H, 4.31; N, 9.99; S, 11.44%. Found: C, 59.89; H, 4.27; N,
9.90; S, 11.37%.
(Z)-Ethyl 4-(4-chlorophenyl)-5-(2-(1-methylbenzimidazol-2-yl)-2-oxo-1-(phenylsulfonyl)-ethylidene)-
4,5-dihydro-1,3,4,thiadiazole-2-carboxylate (27c): Yield (80%), mp > 300 °C; IR (KBr) vmax/cm–1:
1678, 1652 (CO), 1601 (C=N); 1H NMR (DMSO-d6) δ 1.29 (t, 3H, J = 7.2 Hz, CH3), 4.02 (s, 3H, NCH3),
4.23 (q, 2H, J = 7.2 Hz, CH2), 6.85-7.98 (m, 13H, ArH); MS (m/z, %): 580 (M+, 100%); Anal. Calcd for

1840
HETEROCYCLES, Vol. 89, No. 8, 2014
C27H21ClN4O5S2 (581.06): C, 55.81; H, 3.64; N, 9.64; S, 11.04%. Found: C, 55.75; H, 3.56; N, 9.58; S,
10.97%.
(Z)-1-(Benzothiazol-2-yl)-2-(5-benzoyl-3-phenyl-1,3,4-thiadiazole-2-(3H)-ylidene)-2-
(phenylsulfonyl)ethanone (29): Yield (78%), mp 202-204 °C; IR (KBr) vmax/cm–1: 1670, 1652 (CO),
1609 (C=N); 1H NMR (DMSO-d6) δ 6.89-8.14 (m, 19H, ArH); 13C NMR (DMSO-d6) δ 110.05, 118.67,
118.98, 119.84, 120.77, 121.91, 122.90, 124.15, 124.27, 125.32, 128.34, 128.63, 129.02, 129.24,
129.51, 133.40, 137.81, 139.60, 143.03, 147.25, 155.11, 162.73, 182.30, 185.19; MS (m/z, %): 581 (M+,
100%); Anal. Calcd for C30H19N3O4S3 (581.68): C, 61.94; H, 3.29; N, 7.22; S, 16.54%. Found: C, 61.88;
H, 3.21; N, 7.15; S, 16.48%.
(Z)-2-(5-Benzoyl-3-phenyl-1,3,4-thiadiazole-2-(3H)-ylidene)-1-(1-methyl-1H-benzimidazol-2-yl)-2-
(phenylsulfonyl)ethanone (30): Yield (82%), mp 212-214 °C; IR (KBr) vmax/cm–1: 1673, 1648 (CO),
1
1590 (C=N); H NMR (DMSO-d6) δ 4.02 (s, 3H, NCH3), 6.80-7.90 (m, 19H, ArH); MS (m/z, %): 578
(M+, 100%); Anal. Calcd for C31H22N4O4S2 (578.66): C, 64.34; H, 3.83; N, 9.68; S, 11.08%. Found: C,
64.28; H, 3.76; N, 9.59; S, 11.00%.
(Z)-5-(2-(Benzothiazol-2-yl)-2-oxo-1-(phenylsulfonyl)ethylidene)-N-4-diphenyl-4,5-dihydro-1,3,4-
thiadiazole-2-carboxamide (32): Yield (77%), mp 210-212 °C; IR (KBr) vmax/cm–1: 3395 (NH), 1680,
1
1669 (CO), 1601 (C=N); H NMR (DMSO-d6) δ 6.80-8.15 (m, 19H, ArH), 10.60 (s, 1H, D2O-
exchangeable, NH); 13C NMR (DMSO-d ) δ 104.21, 118.89, 119.91, 120.50, 120.94, 122.72, 122.94,
6
124.12, 124.23, 125.29, 128.36, 128.45, 128.62, 129.29, 129.20, 133.33, 138.27, 139.41, 142.16,
147.21, 155.05, 156.32, 162.67, 182.32; MS (m/z, %): 596 (M+, 100%); Anal. Calcd for C30H20N4O4S3
(596.70): C, 60.39; H, 3.38; N, 9.39; S, 16.12%. Found: C, 60.32; H, 3.30; N, 9.29; S, 16.04%.
(Z)-5-(2-(1-Methyl-1H-benzimidazol-2-yl)-2-oxo-1-(phenylsulfonyl)ethylidene)-N-4-diphenyl-4,5-
dihydro-1,3,4-thiadiazole-2-carboxamide (33): Yield (78%), mp 221-223 °C; IR (KBr) vmax/cm–1: 3393
1
(NH), 1677 (CO), 1665 (CO), 1600 (C=N); H NMR (DMSO-d6) δ 4.02 (s, 3H, NCH3), 6.80-7.89 (m,
13
19H, ArH), 10.60 (s, 1H, D2O-exchangeable, NH); C NMR (DMSO-d ) δ 32.23, 104.31, 114.68,
6
115.32, 120.96, 122.75, 122.93, 124.11, 124.30, 128.42, 128.61, 128.73, 129.29, 129.62, 133.68,
134.32, 137.69, 138.28, 141.18, 142.17, 147.09, 155.93, 162.71, 164.17, 182.35; MS (m/z, %): 593 (M+,
100%); Anal. Calcd for C31H23N5O4S2 (593.68): C, 62.72; H, 3.90; N, 11.80; S, 10.80%. Found: C, 62.65;
H, 3.83; N, 11.70; S, 10.72%.
REFERENCES
1. D. Lednicer, ‘Strategies for Organic Drug Synthesis and Design’ John Wiley & Sons, Inc., New York,
2009.

HETEROCYCLES, Vol. 89, No. 8, 2014
1841
2. J. R. Burgeson, A. L. Moore, D. N. Gharaibeh, R. A. Larson, N. R. Cerruti, S. M. Amberg, D. E.
Hruby, and D. Dai, Bioorg. Med. Chem. Lett., 2013, 23, 750.
3. D. Dai, J. R. Burgeson, D. N. Gharaibeh, A. L. Moore, R. A. Larson, N. R. Cerruti, S. M. Amberg, T.
C. Bolken, and D. E. Hruby, Bioorg. Med. Chem. Lett., 2013, 23, 744.
4. M. S. Abu-Bakr, F. A. Bassyouni, and M. Abdel Rehim, Res. Chem. Intermed., 2012, 38, 2523.
5. D. L. Evers, G. Komazin, D. Shin, D. D. Hwang, L. B. Townsend, and J. C. Drach, Antiviral Res.,
2002, 56, 61.
6. Z. Kazimierczuk, M. Andrzejewska, J. Kaustova, and V. Klimesova, Eur. J. Med. Chem., 2005, 40,
203.
7. Y. He, J. Yang, B. Wu, L. Risen, and E. E. Swayze, Bioorg. Med. Chem. Lett., 2004, 14, 1217.
8. B. Nandha, H. Kuntal, J. N. N. S. Chandra, L. V. G. Nargund, P. Rashmi, M. S. Harish, and D. S.
Puranik, Pharma Chemica, 2013, 5, 287.
9. Y.-B. Bai, A.-L. Zhang, J.-J. Tang, and J.-M. Gao, J. Agric. Food Chem., 2013, 61, 2789.
10. Y. L. N. Murthy, G. Durga, and A. Jha, Med. Chem. Res., 2013, 22, 2266.
11. P. Z. Zhang, S. F. Zhou, T. R. Li, and L. Jiang, Chin. Chem. Lett., 2012, 23, 1381.
12. G. Singh, M. Kaur, and M. Chander, Int. Res. J. Pharm., 2013, 4, 82.
13. V. Vajpayee, S. Lee, J. W. Park, A. Dubey, H. Kim, T. R. Cook, P. J. Stang, and K.-W. Chi,
Organometallics, 2013, 32, 1563.
14. R. A. Haque, M. A. Iqbal, M. B. K. Ahamed, A. M. S. Abdul Majid, and Z. A. Abdul Hameed, Chem.
Cent. J., 2012, 6, 68.
15. A. Husain, M. Rashid, M. Shaharyar, A. A. Siddiqui, and R. Mishra, Eur. J. Med. Chem., 2013, 62,
785.
16. S. -T. Huang, I. -J. Hsei, and C. Chen, Bioorg. Med. Chem., 2006, 14, 6106.
17. V. R. Solomon, C. Hu, and H. Lee, Bioorg. Med. Chem., 2009, 17, 7585.
18. Q. Huang, J. Mao, B. Wan, Y. Wang, R. Brun, S. G. Franzblau, and A. P. Kozikowski, J. Med. Chem.,
2009, 52, 6757.
19. V. N. Telvekar, V. K. Bairwa, K. Satardekar, and A. Bellubi, Bioorg. Med. Chem. Lett., 2012, 22,
649.
20. A. Burger and S. N. Sawhney, J. Med. Chem., 1968, 11, 270.
21. R. D. Chakole, N. D. Amnerkar, P. B. Khedekar, and K. P. Bhusari, Indian J. Heterocycl. Chem.,
2005, 15, 27.
22. A. T. Mavrova, K. K. Anichina, D. I. Vuchev, J. A. Tsenov, P. S. Denkova, M. S. Kondeva, and M. K.
Micheva, Eur. J. Med. Chem., 2006, 41, 1412.
23. M. Mor, F. Bordi, C. Silva, S. Rivara, V. Zuliani, F. Vacondio, M. Rivara, E. Barocelli, S. Bertoni,

1842
HETEROCYCLES, Vol. 89, No. 8, 2014
and V. Ballabeni, Bioorg. Med. Chem., 2004, 12, 663.
24. D. T. Nannapaneni, A. V. S. S. S. Gupta, M. I. Reddy, and R. C. Sarva, J. Young Pharm., 2010, 2,
273.
25. N. Siddiqui, M. Alam, and A. A. Siddiqui, Asian J. Chem., 2004, 16, 1005.
26. S. M. Sondhi, S. Rajvanshi, M. Johar, N. Bharti, A. Azam, and A. K. Singh, Eur. J. Med. Chem., 2002,
37, 835.
27. B. M. Gurupadayya, M. Gopal, B. Padmashali, and V. P. Vaidya, Indian J. Heterocycl. Chem., 2005,
15, 169.
28. D. Evans, T. A. Hicks, W. R. N. Williamson, W. Dawson, S. C. R. Meacock, and E. A. Kitchen, Eur.
J. Med. Chem.,1996, 31, 635.
29. H. M. Diaz, R. V. Molina, R. O. Andrade, D. D. Coutino, L. M. Franco, S. P. Webster, M. Binnie, S.
E. Soto, M. I. Barajas, I. L. Rivera, and G. N. Vazquez, Bioorg. Med. Chem. Lett., 2008, 18, 2871.
30. A. Rao, A. Chimirri, E. De Clercq, A. M. Monforte, P. Monforte, C. Pannecouque, and M. Zappala, Il
Farmaco, 2002, 57, 819.
31. A. Chimirri, E. De Clercq, A. M. Monforte, P. Monforte, C. Pannecouque, A. Rao, M. Witvrouw, and
M. Zappalà, Antiviral Res., 2000, 46, A41.
32. W. W. Mederski, D. Dorsch, S. Anzali, J. Gleitz, B. Cezanne, and C. Tsaklakidis, Bioorg. Med. Chem.
Lett., 2004, 14, 3763.
33. H. Göker, G. Ayhan, M. Tunçbilek, R. Ertan, G. Leoncini, R. Garzoglio, and M. Mazzei, Eur. J. Med.
Chem., 1995, 30, 561.
34. L. M. Yagupolskii and D. V. Fedyuk, Tetrahedron Lett., 2000, 41, 2265.
35. T. Varming, P. Christophersen, A. Møller, D. Peters, O. Axelsson, and E. Ø. Nielsen, Bioorg. Med.
Chem. Lett., 1996, 6, 245.
36. E. A. M. Badawey and T. Kappe, Eur. J. Med. Chem., 1999, 34, 663.
37. E. A. M. Badawey and T. Kappe, Eur. J. Med. Chem., 1995, 30, 327.
38. B. E. Maryanoff, S. O. Nortey, J. J. McNally, P. J. Sanfilippo, D. F. McComsey, B. Dubinsky, R. P.
Shank, and A. B. Reitz, Bioorg. Med. Chem. Lett., 1999, 9, 1547.
39. B. E. Maryanoff, D. F. McComsey, W. Ho, R. P. Shank, and B. Dubinsky, Bioorg. Med. Chem. Lett.,
1996, 6, 333.
40. E. A. Averkin, C. C. Beard, C. A. Dvorak, J. A. Edwards, J. H. Fried, J. G. Kilian, R. A. Schiltz, T. P.
Kistner, and J. H. Drudge, J. Med. Chem., 1975, 18, 1164.
41. W. Beil, H. Hannemann, S. Maedge, and K. F. Sewing, Eur. J. Pharmacol., 1987, 133, 37.
42. W. A. Simon, C. Büdingen, S. Fahr, B. Kinder, and M. Koska, Biochem. Pharmacol., 1991, 42, 347.
43. K. Ramaiah, P. K. Dubey, J. Ramanadham, J. S. Grossert, and D. L. Hooper, Ind. J. Chem., 1999, 38,

HETEROCYCLES, Vol. 89, No. 8, 2014
1843
297; B. M. Trost and D. P. Curran, Tetrahedron Lett., 1981, 22, 1287; H. D. Becker and G. A. Russel,
J. Org. Chem., 1963, 28, 1896.
44. P. D. Magnus, Tetrahedron, 1977, 33, 2019.
45. E. S. Darwish, K. A. Atia, and A. M. Farag, Heterocycles, 2014, 89, 1393.
46. A. F. Darweesh, A. E. M. Mekky, A. A. Salman, and A. M. Farag, Heterocycles, 2014, 89, 113.
47. Y. N. Mabkhot, N. A. Kheder, and A. M. Farag, Molecules, 2013, 18, 4669.
48. B. Hegazi, H. Abdel-Gawad, H. A. Mohamed, F. A. Badria, and A. M. Farag, J. Heterocycl. Chem.,
2013, 50, 355.
49. K. A. Ali, M. A. Elsayed, and A. M. Farag, Heterocycles, 2012, 85, 1913.
50. M. R. Shaaban, T. S. Saleh, A. S. Mayhoub, and A. M. Farag, Eur. J. Med. Chem., 2011, 46, 3690.
51. Y. N. Mabkhot, N. A. Kheder, and A. M. Farag, Heterocycles, 2011, 83, 609.
52. A. M. Farag, K. A. K Ali, T. El-Debss, A. S Mayhoub, A. E Amr, N. A. Abdel-Hafez, and M. M
Abdulla, Eur. J. Med. Chem., 2010, 45, 5887.
53. E. S. Darwish, N. A. Kheder, and A. M. Farag, Heterocycles, 2010, 81, 2247.
54. Y. N. Mabkhot, N. A. Kheder, and A. M. Farag, Heterocsycles, 2010, 81, 2369.
55. A. M. Farag, N. A. Kheder, and Y. N. Mabkhot, Heterocycles, 2009, 78, 1787.
56. N. A. Kheder, Y. N. Mabkhot, and A. M. Farag, Heterocycles, 2009, 78, 937.
57. M. R. Shaaban, T. S. Saleh, and A. M. Farag, Heterocycles, 2009, 78, 151.
58. A. M. Farag, A. S. Mayhoub, S. E. Barakat, and A. H. Bayomi, Bioorg. Med. Chem., 2008, 16, 881.
59. A. M. Farag, A. S. Mayhoub, S. E. Barakat, and A. H. Bayomi, Bioorg. Med. Chem., 2008, 16, 4569.
60. M. R. Shaaban, T. S. Saleh, A. S. Mayhoub, A. Mansour, and A. M. Farag, Bioorg. Med. Chem., 2008,
16, 6344.